Organic Active Ingredients TRIZ Cases

Modifying indazole substituents achieves effective ERK1/2 inhibition to overcome the lack of potent inhibitors in current anticancer therapies.

Novel pyridinaminosulfonyl benzamide compounds inhibit the CYP3A4 enzyme to boost antiretroviral drug exposure.

Biotin-manganese complex stabilizes oxaloacetate delivery, preventing rapid degradation while sustaining enhanced metabolic energy efficiency.

Thiazolyl dihydro-indazoles inhibit cell cycle kinases to treat diseases characterized by abnormal cell proliferation.

Histidine-lysine polymer carrier protects siRNA from degradation, enabling effective MyD88 and TGF-beta1 gene silencing in cancer cells.

Pre-coated naltrexone microspheres withstand tableting pressure without rupture, while suspended drying prevents adhesion for uniform sustained release.

Small molecule furin inhibitor formulation improves chemical stability and pharmacokinetic properties compared to peptide derivatives.

A HER2 aptamer-anticancer drug complex links a targeting nucleic acid to a therapeutic agent via a disulfide bond.

Non-reducible sugar diluents prevent Maillard degradation and oxidation in omarigliptin tablets, maintaining less than 0.5% degradants.

A Dll4 function inhibitor suppresses Notch2 activation in myofibers to treat muscular atrophy.

Cannabinol derivatives at 0.15 to 15 μM inhibit retinal neuron apoptosis, halting glaucoma progression independent of intraocular pressure reduction.

Antisense oligonucleotides target ATN1 mRNA to inhibit mutant protein expression, addressing low treatment satisfaction in DRPLA.

Self-assembling prodrugs form tubular supramolecular polymers to mask pharmaceutical activity until dissociation restores potency.

Ligating hairpin-shaped DNA to nucleic acid ends resists enzymatic degradation without cyclization or unnatural analogues, simplifying manufacturing.

Formula I compounds inhibit GRK6 polypeptides, addressing inadequate targeting of cell proliferation pathways in inflammation and autoimmune disorders.

Gel-forming injectable composition containing deoxycholic acid and amino acids limits inflammation during localized fat reduction.

Kinase inhibitors mediate immune signaling to prevent cytokine release syndrome while preserving anti-tumor efficacy of CAR T cells.

Combining bisphosphonates with gamma-delta CAR T cells boosts cytotoxic activity to reduce tumor growth and improve survival in bone metastatic prostate cancer.

Controlled release nefopam maintains analgesic efficacy while reducing adverse drug reactions from plasma peaks.

Fused heterocyclic compounds inhibit EHMT2 to resolve development complexity from selectivity requirements.

Substituted piperazine rings in heterocyclic derivatives increase HCMV inhibition potency by 8 to 40 folds while reducing nephrotoxicity risks.

A multispecies probiotic composition alleviates self-reported mental exhaustion through synergistic bacterial strains.

Serotonin receptor antagonists block gut receptors activated by Cbl inhibitors, reducing nausea and enabling higher therapeutic doses.

Thiazoloxime derivatives restore enzyme activity by attacking phosphonate groups, overcoming rapid clearance and blood-brain barrier limits of standard oximes.

Trichostatin A targets cancer stem cells by downregulating CCNB1 and AURKB genes, preventing recurrence after initial chemotherapy response.

Hydroxylated VLC-PUFAs abrogate pro-inflammatory cytokine production, reducing senescent cell activity and treating age-related diseases.

Novel alpha-v-beta-6 integrin inhibitor compounds featuring pyrrolidinone scaffolds and lipophilic groups enable oral delivery of potent small molecules.

Alkaloid composition reduces inflammatory markers and fibrosis proteins to treat chronic obstructive pulmonary disease.

Single-pass tangential flow filtration concentrates antibody drug conjugates while removing unconjugated drugs through continuous membrane separation.

Cyclodextrin encapsulates disodium phosphocreatine, preventing gastric degradation and enhancing intestinal bioavailability.

Formula I compounds inhibit LMTK3 via structure-based drug design, overcoming resistance from aberrant complementary kinase activation.

Segmented psilocin dimers and trimers improve therapeutic efficacy while managing structural complexity.

Selective MRGPRD modulators target the receptor directly, resolving inadequate efficacy in managing pain and inflammation.

A potassium-free alkalizing tablet uses sustained release to maintain urine pH within a therapeutic range.

Matching melting temperatures stabilizes lipid carriers within ethylene vinyl acetate copolymers, enabling controlled release without degradation.

Segmented molecular structures with variable substituents modulate receptor activity to treat cancer by restoring impaired immune responses.

Dimethylfumarate alleviates renal fibrosis by activating Nrf2 to inhibit TGF-β/Smad signaling, addressing ineffective conventional therapies.

Body surface area dosing resolves unpredictable pharmacokinetic exposure in non-adult subjects treated with anti-CD30 antibody-drug conjugates.

Formula I compounds inhibit APOL1 activity, reducing proteinuria and slowing kidney function decline in FSGS and NDKD patients.

Modified aminopyrazine structures overcome drug resistance and reduce side effects while maintaining potent antimalarial efficacy.

Administering a RUNX3 inhibitor modulates migratory capabilities and microenvironment, reducing metastatic potential and mortality in pancreatic cancer.

Laser radiation cures siloxane adhesive rapidly, preventing heat damage to active agents during manufacturing.

Lipid nanoparticles protect nucleic acids from degradation and enhance cellular uptake to improve therapeutic efficacy.

Increasing miR-29 levels inhibits BH3-only gene expression, enhancing neuronal resistance to ischemic damage and trauma.

Segmented sugar-linker-drug conjugates resolve antitumor efficacy versus toxicity trade-offs by selectively binding cancer cells and releasing drugs locally.

Cell membrane lipid-extracted nanoliposomes resolve formulation stability versus selective targeting contradictions by incorporating tumor-derived lipids.

Imidazopyridinone compounds inhibit prolyl hydroxylase 2 to stabilize hypoxia-inducible factor alpha.

Segmenting UV and LED modules deactivates pathogens while minimizing host cell DNA damage risk in the polychromatic phototherapy device.

Genetically modified Bacillus strains produce fucosylated oligosaccharides via metabolic engineering, resolving contamination risks from chemical synthesis.

Segmented dsRNA agents with lipophilic moieties reduce APOE expression, addressing treatment complexity in neurodegenerative disease management.

Modifying molecular parameters of the bicyclic himbacine core extends half-life while reducing side effects for cardiovascular treatment.

Diaryl thioether piperazine compounds extend antidepressant efficacy duration by modifying chemical structure to balance solubility and slow release rates.

Substituted indole derivatives modulate gamma-secretase activity, improving metabolic stability and central brain availability while reducing CYP inhibition.

A CRISPR-GNDM system targets KRAS regulatory regions to suppress gene expression.

Replacing metallic salts with non-metallic alternatives prevents impurity formation and degradation of the active ingredient during storage.

Lef-1 transcription factor drives glandular myoepithelial cell proliferation and differentiation into multipotent basal cells.

Fish gelatin prevents nanoparticle aggregation during freeze-drying, maintaining dissolution rates for poorly water-soluble drugs.

Combines lactic acid bacteria with vitamin C to activate antioxidant enzymes.

A hydrogel carrier encapsulates proline hydroxylase inhibitors to stabilize HIF1α levels and promote tissue regeneration.

Composite acrylate and cationic acrylic copolymer adhesive provides sustained rasagiline release over seven days, resolving formulation stability limits.

Peptidomimetic compounds inhibit viral protease activity through targeted binding to active sites.

Cellulose derivatives buffer aqueous interactions to resolve the contradiction between brivaracetam solubility and chemical stability.

Melatonin gel prevents chemotherapy-induced mucositis by scavenging free radicals, maintaining cancer treatment continuity.

Dihydroquercetin suppresses blood lactic acid levels while potentiating metformin's anti-malignant tumor effect, resolving severe lactic acidosis side effects.

Glutaurine acts as an intermediary to resolve the contradiction between improved metabolism and thyroid atrophy, maintaining gland health.

Replacing rasagiline mesylate with a L-tartrate and L-tartaric acid eutectic system reduces mannitol loading while maintaining content uniformity.

Bixin blocks KEAP1-mediated ubiquitylation of NRF2, inducing cytoprotective mechanisms that prevent ventilator-induced lung injury.

Overexpressing AtAIRP2 E3 ubiquitin ligase increases drought and salt resistance in transgenic plants.

Introducing sugar moieties to the phthalimide amino group improves water solubility, enabling injectable formulations while reducing teratogenic side effects.

Segregation of stereoselective Suzuki coupling and cyclization steps improves yield and stability of crystalline phenyltriazolyl acrylamides.

Tetracyclic oxazepine compounds modulate mutant KRas activity, addressing prolonged protein activation in G12D-mediated cancers.

Systematic derivatization of Leptomycin B reduces gastrointestinal toxicity while maintaining CRM1 inhibition efficacy.

Replacing toxic N-methyl pyrolidone with safer solvents eliminates safety concerns while maintaining sustained release duration and high drug load.

Combining dextromethorphan with a CYP2D6 inhibitor extends therapeutic duration and provides neuroprotection against neuropsychiatric symptoms.

Reductive amination using sodium triacetoxyborohydride establishes chiral centers in NEP inhibitor synthesis.

A prodrug spacer bearing a protected nitrogen nucleophile undergoes enzymatic cleavage to trigger intra-molecular cyclization.

Hydrophilic polyamide structures reduce blood-brain barrier penetration to lower side effects while maintaining potent kappa-opioid receptor agonism.

A radiocontrast medium containing a calcineurin inhibitor reduces inflammatory upregulation in renal tubular cells.

Segmented pyrrolo[2,3-d]pyrimidine derivatives target RET kinases to resolve limited therapeutic agent availability.

Specialized polymer matrix binds paclitaxel to prevent transit loss and systemic embolization while ensuring controlled release to the vessel wall.

Neutral beam irradiation creates a pure drug barrier layer on medical devices, eliminating toxic polymer binders and preventing delamination.

Modulating KRAB zinc finger proteins reverses epigenetic resistance in ABC DLBCL, restoring sensitivity to standard chemotherapy.

Targeting Src and p190GAP blocks BAD mitochondrial translocation, reducing TNF-alpha cytotoxicity while preserving anti-inflammatory efficacy.

Specific small molecule compounds inhibit chymase to lower angiotensin II levels, addressing the lack of effective treatments for chronic heart failure.

Synergizes PIM kinase and autophagy inhibitors to block cancer proliferation, overcoming drug resistance by targeting downstream survival pathways.

Humanin peptide binds IGFBP-3 to prevent autoimmune beta cell destruction and delay type 1 diabetes onset.

Specific phenothiazine derivatives target and inhibit toxic Aβ oligomer formation to address Alzheimer's disease pathology.

Levorotatory epinephrine formulations maintain high purity through precise pH adjustment and inert nitrogen sterilization.

Functionalized nanoparticles produce photoacoustic signals to visualize tumors smaller than 3 mm, overcoming conventional imaging resolution limits.

Segmented corticosteroid microparticle formulations provide sustained local release to minimize HPA axis suppression and systemic side effects.